SCHEMBL2128569

SCHEMBL2128569

Cc1cc(Cl)nc(Cl)c1C(=O)NCc1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 1.00
MEN1 O00255 5/20 1.00
TAAR1 Q96RJ0 1/20 0.61
SMN1; SMN2 Q16637 4/20 0.53
LMNA P02545 3/20 0.53
ALDH1A1 P00352 2/20 0.53
TSHR P16473 1/20 0.53
HPGD P15428 2/20 0.52
THRB P10828 1/20 0.51
NPC1 O15118 1/20 0.50
CHRM4 P08173 1/20 0.49
RAB9A P51151 2/20 0.49
GALR3 O60755 1/20 0.49
NR2F2 P24468 1/20 0.49
CYP1A1 P04798 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2128166 0.89 KMT2A (0.81) KMT2AMEN1TAAR1SMN1; SMN2ALDH1A1
SCHEMBL2129169 0.86 KMT2A (0.75) KMT2AMEN1TAAR1SMN1; SMN2LMNA
SCHEMBL2130294 0.82 KMT2A (0.70) KMT2AMEN1TAAR1SMN1; SMN2ALDH1A1
SCHEMBL2129852 0.81 MEN1 (0.67) KMT2AMEN1TAAR1SMN1; SMN2LMNA
SCHEMBL2131055 0.74 KMT2A (0.59) KMT2AMEN1TAAR1SMN1; SMN2LMNA
SCHEMBL13235115 0.74 MEN1 (0.65) KMT2AMEN1TAAR1SMN1; SMN2ALDH1A1
SCHEMBL23718206 0.74 MEN1 (0.57) KMT2AMEN1TAAR1SMN1; SMN2ALDH1A1
SCHEMBL15328649 0.73 KMT2A (0.57) KMT2AMEN1ALDH1A1HPGDTHRB
SCHEMBL11922249 0.73 MEN1 (0.57) KMT2AMEN1TAAR1NPC1CHRM4
SCHEMBL27106875 0.72 MEN1 (0.56) KMT2AMEN1SMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3318556-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2018-05-09 EP disclosed
EP-2630123-B1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS GRUENENTHAL GMBH (DE) 2017-12-20 EP disclosed
US-9278103-B2 Substituted 6-amino-nicotinamides as KCNQ2/3 modulators Grünenthal GmbH (DE) 2016-03-08 US disclosed
US-9168259-B2 Substituted 6-amino-nicotinamides as KCNQ2/3 modulators Grünenthal GmbH (DE) 2015-10-27 US disclosed
US-20140213569-A1 Substituted 6-amino-nicotinamides as KCNQ2/3 modulators GRUNENTHAL GMBH (DE) 2014-07-31 US disclosed
US-8552200-B2 Substituted 6-amino-nicotinamides as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-10-08 US disclosed
EP-2630123-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2013-08-28 EP disclosed
US-20120258947-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS GRUNENTHAL GMBH (DE) 2012-10-11 US disclosed
US-20120101079-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS GRUNENTHAL GMBH (DE) 2012-04-26 US disclosed
WO-2012052167-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213569-A1 Substituted 6-amino-nicotinamides as KCNQ2/3 modulators KCNQ2, KCNQ1, KCNQ3 KMT2A 403/4885MEN1 3018/4885TAAR1 2552/4885
US-20120101079-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS KCNQ2, KCNQ1, KCNQ3 KMT2A 403/4885MEN1 3018/4885TAAR1 2552/4885
US-20120258947-A1 SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS KCNQ2, KCNQ1, KCNQ3 KMT2A 403/4885MEN1 3018/4885TAAR1 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.